Journal Title：Current Hypertension Reports

This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hypertension.

We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as antihypertensive therapies, associated metabolic disorders, and therapeutic trials. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

本期刊旨在提供國際專家的清晰、有見地、平衡的貢獻，回顧與高血壓診斷、治療、管理和預防相關的最重要的、最近發(fā)表的臨床發(fā)現(xiàn)。

我們通過任命國際權威人士擔任關鍵主題領域的分部編輯來實現(xiàn)這一目標，例如抗高血壓治療、相關代謝紊亂和治療試驗。分部編輯依次選擇主題，由頂尖專家撰寫全面的評論文章，強調(diào)新發(fā)展和最近發(fā)表的重要論文，并通過帶注釋的參考文獻列表突出顯示。國際編輯委員會審查年度目錄，推薦對其國家/地區(qū)特別感興趣的文章，并確保主題是最新的并包括新興研究。還提供該領域知名人物的評論。

Current Hypertension Reports創(chuàng)刊于1999年，由Springer US出版商出版，收稿方向涵蓋醫(yī)學 - 外周血管病全領域，此刊是該細分領域中屬于非常不錯的SCI期刊，在行業(yè)細分領域中學術影響力較大，專業(yè)度認可很高，所以對原創(chuàng)文章要求創(chuàng)新性較高，如果您的文章質(zhì)量很高，可以嘗試。平均審稿速度 較慢,6-12周 ，影響因子指數(shù)3.9，該期刊近期沒有被列入國際期刊預警名單，廣大學者值得一試。